Price Action Report: CoLucid Pharmaceuticals Inc Surges to Record High, Is Now Top Performer

Price Action Report: CoLucid Pharmaceuticals Inc Surges to Record High, Is Now Top Performer

The stock of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) reached all time high today, Sep, 30 and still has $57.43 target or 67.00% above today’s $34.39 share price. This indicates more upside for the $636.15M company. This technical setup was reported by If the $57.43 PT is reached, the company will be worth $426.22M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 59,237 shares traded hands. CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has risen 513.78% since February 26, 2016 and is uptrending. It has outperformed by 503.36% the S&P500.

Analysts await CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) to report earnings on November, 8. They expect $-0.97 EPS, down 64.41% or $0.38 from last year’s $-0.59 per share. After $-1.06 actual EPS reported by CoLucid Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -8.49% EPS growth.

CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Ratings Coverage

Out of 2 analysts covering CoLucid Pharmaceuticals (NASDAQ:CLCD), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. $30 is the highest target while $22 is the lowest. The $26 average target is -24.40% below today’s ($34.39) stock price. CoLucid Pharmaceuticals has been the topic of 3 analyst reports since August 14, 2015 according to StockzIntelligence Inc. On Thursday, September 3 the stock rating was upgraded by Zacks to “Hold”. The firm has “Buy” rating by Stifel Nicolaus given on Monday, September 19. William Blair maintained the stock with “Buy” rating in Friday, August 14 report.

According to Zacks Investment Research, “CoLucid Pharmaceuticals, Inc. is a biopharmaceutical company which develops molecule for the treatment of migraine headaches. The company’s product candidate consists of oral Lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain, which are in different clinical trial. CoLucid Pharmaceuticals, Inc. is headquartered in Burlington, Massachusetts.”

More news for CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) were recently published by:, which released: “Why CoLucid Pharmaceuticals Inc. Soared As Much As 18% on Thursday” on September 15, 2016.‘s article titled: “CORRECTING and REPLACING – CoLucid Pharmaceuticals Provides Interim Update on …” and published on September 19, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment